Minimally invasive lung adenocarcinoma, Mycobacterium avium intracellulare and Langerhans histiocytosis
DOI:
https://doi.org/10.2478/AMB-2025-0063Keywords:
lung adenocarcinoma, minimally invasive, Mycobacterium avium, Langerhans cell histiocytosis, case reportAbstract
Adenocarcinoma of the lung is the most common lung tumor, accounting for about 40% of the cases. Minimally invasive adenocarcinoma may be a part of a continuum of morphological changes, leading to the development of invasive adenocarcinoma of the lung. It is defined as a predominantly lepidic lesion measuring ≤3.0 cm with only small foci of invasion, the largest of which should be less than 0.5 cm. An association between lung cancer, Mycobacterium avium infection and Langerhans cell histiocytosis has already been described in past studies. We present a case of a 59-year-old patient with PET/CT data for metabolically active tumor (28 mm), which had increased in size and activity compared to the previous scan. On admission to our hospital, he had undergone 14 courses of chemotherapy at another institution for diffuse large B-cell lymphoma (DLBCL). After the left upper lobectomy, minimally invasive lung adenocarcinoma, Mycobacterium avium intracellulare and accompanying Langerhans cell histiocytosis were histologically verified.
References
Hu X, Fujimoto J, Ying L, et al. Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Nat Commun. 2019:5;10(1):2978. doi: 10.1038/s41467-019-10877-8. Erratum in: Nat Commun. 2021;12;12(1):2888.
Sami M, Fibi N. Mycobacterium avium Complex. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024; Feb 25.
Pina-Oviedo S, Medeiros LJ, Li S, et al. Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations. Mod Pathol. 2017;30(5):734-744. doi: 10.1038/modpathol.2016.235.
Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367-416.
Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J 2020; 56: 2000535, https://doi.org/10.1183/13993003.00535-2020.
WHO Classification of Tumours Editorial Board. Thoracic tumours. Lyon (France): International Agency for Research on Cancer; 2021. (WHO classification of tumours series, 5th ed.; vol. 5).
Kadata K, Villena-Vargas J, Yoshizawa A, et al. Prognostic Significance of Adenocarcinoma in situ, Minimally Invasive Adenocarcinoma, and Nonmucinous Lepidic Predominant Invasive Adenocarcinoma of the Lung in Patients with Stage I Disease. Am J Surg Pathol. 2014; 38(4): 448–460.
Strand T, Rostad H, Strøm E, Hasleton Ph. The percentage of lepidic growth is an independent prognostic factor in invasive adenocarcinoma of the lung. Diagn Pathol. 2015; 10: 94.
Chakraborty RK, Sharma S. Bronchoalveolar Cancer. StatPearls Treasure Island: StatPearls Publishing; 2024. //www.ncbi.nlm.nih.gov/books/NBK513281/
Suzuki S, Sakurai H, Masai K, et al. Departments of Thoracic Surgery and Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo; and Division of Respiratory Surgery, Nihon University School of Medicine, Tokyo, Japan. A Proposal for Definition of Minimally Invasive Adenocarcinoma of the Lung Regardless of Tumor Size. J Thorac Oncol. 2017 Dec;12(12):1788-1797. doi: 10.1016/j.jtho.2017.08.015. Epub 2017 Sep 4.2017;104:1027–32
Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011;24(5):653-64. doi: 10.1038/modpathol.2010.232.
Tsuta K, Kawago M, Inoue E, et al. The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. Lung Cancer. 2013;81(3):371-376. doi: 10.1016/j.lungcan.2013.06.012.
Takahiro M, Morihito O, Man H, et al. Upregulation of Notch2 and Six1 Is Associated with Progression of Early-Stage Lung Adenocarcinoma and a More Aggressive Phenotype at Advanced Stages. doi: 10.1158/1078-0432.CCR-11-1946
Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 201016; 116(11):1919-23. doi: 10.1182/blood-2010-04-279083.
Tomashefski JF, Khiyami A, Kleinerman J. Neoplasms associated with pulmonary eosinophilic granuloma. Arch Pathol Lab Med. 1991;115(5):499-506.
Egeler RM, Neglia JP, Puccetti DM, et al. Association of Langerhans cell histiocytosis with malignant neoplasms. Cancer. 1993:1;71(3):865-73. doi: 10.1002/1097-0142(19930201)71:3<865::aid-cncr2820710334>3.0.co;2-0.
Atsuhisa T, Akira H, Kei K, et al. Relationship Between Lung Cancer and Mycobacterium Avium Complex Isolated Using Bronchoscopy. Open Respir Med J. 2016; 10: 20–28.
Lande L, Peterson DD, Gogoi R, et al. Association between pulmonary mycobacterium avium complex infection and lung cancer. J Thorac Oncol 2012; 7:1345-51.
Fujita K, Yamamoto Y, Kanai O, et al. Development of Mycobacterium avium complex lung disease in patients with lung cancer on immune checkpoint inhibitors. Open Forum Infect Dis 2020; 7:ofaa067.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 S. Ivanova, R. Cherneva, R. Krasteva, Z. Makshutova, G. Yankov (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to share, copy and redistribute the material in any medium or format under these terms.
Journal Acta Medica Bulgarica 
